3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Unknown
2
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
7
Leukemia, Myeloid, Acute
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia
2
Head and Neck Neoplasms
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
Bevacizumab
47
lenvatinib
36
atezolizumab
36
durvalumab
28
tremelimumab
23
sintilimab
19
Nivolumab
18
pembrolizumab
14
Radiosurgery
13
tislelizumab
11
Specimen Handling
10
Ipilimumab
10
camrelizumab
8
apatinib
8
Oxaliplatin
8
Immune Checkpoint Inhibitors
8
Fluorouracil
8
Cyclophosphamide
8
Blood Specimen Collection
8
regorafenib
7
cabozantinib
7
fludarabine
6
Sorafenib
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
donafenib
5
Surgical Procedures, Operative
5
Injections
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Hepatocellular
×
Interleukin-2
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled